人肝癌多药耐药细胞模型的建立  

Establishment of Multidrug Resistance Cell Sublines of Humal Liver Cancer

作　　者：刘景丰[1] 洪伟[1] 

机构地区：[1]福建医科大学附属第一医院肝脏外科中心,福建福州350005

出　　处：《中西医结合肝病杂志》2003年第S1期-,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:为研究肝癌多药耐药(MDR)机制,采用5种抗癌药物通过不同的诱导方式建立一组人肝癌MDR细胞模型。方法:利用RT-PCR、流式细胞术和四甲基偶氮唑盐(MTT)法测定MDR细胞中5种MDR基因的表达及耐药倍数。结果:SMMC7721/DOX亚系由mdr_1基因介导耐药,SMMC7721/VCR亚系由MRP基因介导耐药,SMMC7721/CBP亚系由LRP基因介导耐药,SMMC7721/VP16亚系由TopoⅡα基因介导耐药,SMMC7721/MMC亚系由GST_(P1)基因介导耐药,多重MDR亚系SMMC7721/M的耐药涉及mdr_1、MRP、URP、TopoⅡα和GST_(P1)。结论:MDR细胞模型可用于耐药研究。Objective: To study multidrug resistance (MDR) mechanism of hepatocellular carcinoma (HCC). Methods: By using five kinds of chemotheraputic agents, a group of MDR cell sublines in HCC cell were successfully established. Results: Observation on model s drug resistance mechanism revealed that drug resistance in SMMC7721/DOX subline was mediated by mdr1 gene; similarly was that the SMMC7721/VCR subline mediated by MRP gene; SMMC7721/CBP subline by LRP gene; SMMC7721/VP16 subline by TopoⅡα gene; and SMMC7721/MM...

关 键 词：癌 肝细胞 多药耐药 细胞模型 

分 类 号：R735.7[医药卫生—肿瘤]